The Royal College of Ophthalmologists welcomes the SMC decision to recommend Aflibercept (Eylea®) as a treatment for neovascular AMD Aflibercept is a soluble vascular endothelial growth factor (VEGF) receptor fusion protein which binds to all forms of VEGF and inhibits its actions